Abstract
Richter syndrome (RS) arising from chronic lymphocytic leukemia (CLL) exemplifies an aggressive malignancy that develops from an indolent neoplasm. To decipher the genetics underlying this transformation, we computationally deconvoluted admixtures of CLL and RS cells from 52 patients with RS, evaluating paired CLL–RS whole-exome sequencing data. We discovered RS-specific somatic driver mutations (including IRF2BP2, SRSF1, B2M, DNMT3A and CCND3), recurrent copy-number alterations beyond del(9p21)(CDKN2A/B), whole-genome duplication and chromothripsis, which were confirmed in 45 independent RS cases and in an external set of RS whole genomes. Through unsupervised clustering, clonally related RS was largely distinct from diffuse large B cell lymphoma. We distinguished pathways that were dysregulated in RS versus CLL, and detected clonal evolution of transformation at single-cell resolution, identifying intermediate cell states. Our study defines distinct molecular subtypes of RS and highlights cell-free DNA analysis as a potential tool for early diagnosis and monitoring.
Original language | English |
---|---|
Pages (from-to) | 158-169 |
Number of pages | 12 |
Journal | Nature Medicine |
Volume | 29 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2023 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2023, The Author(s), under exclusive licence to Springer Nature America, Inc.
Funding
We thank C. Hahn, E. Ten Hacken, W. Zhang, S. Gohil and L. Werner for helpful discussions. We thank C. Patterson, S. Pollock, O. Olive, C. J. Shaughnessy, F. Dao and H. Lyon for assistance in data collection and organization and S. Belkin and C. Birger for assistance in data storage. We thank T. Lehmberg, M. McDonough, C. Galler and M. Collins for assistance in sample collection and biobanking. We thank the patients, their families and the investigators of the clinical trials for providing samples and clinical data. This study was supported by NIH/NCI P01 CA206978 (to C.J.W. and G.G.) and NCI (1U10CA180861-01) (to C.J.W.). The work is partially supported by the Broad/IBM Cancer Resistance Research Project (I.L., G.G. and L.P.) and a grant from Force Hemato (R.G.). Individual support was provided by DDCF Physician-Scientist Fellowship (E.M.P.), Dana-Farber Flames FLAIR fellowship (E.M.P.), ASCO Conquer Cancer Young Investigator Award (E.M.P.), Fishman Family Fund (R.G. and C.L.), EMBO fellowship ALTF 14-2018 (B.A.K.), NCI Research Specialist Award R50CA251956 (S.L.) and NIH/NCI R21CA267527-01 (S.Y.). Additional research support was provided by NIH R01 CA213442 (J.R.B.), Melton Family Foundation (J.R.B.), NIH/NCI R01-CA236361 (T.J.K.) and the Deutsche Forschungsgemeinschaft (DFG) SFB1074 subprojects B10 (E.T.) and subprojects B1 and B2 (E.T., C.S. and S.S.)
Funders | Funder number |
---|---|
ASCO Conquer Cancer | |
Dana-Farber Flames | |
Fishman Family Fund | |
Force Hemato | |
Melton Family Foundation | R01-CA236361 |
National Institutes of Health | |
National Cancer Institute | P01 CA206978, 1U10CA180861-01 |
Doris Duke Charitable Foundation | |
European Molecular Biology Organization | R50CA251956, ALTF 14-2018, R21CA267527-01, R01 CA213442 |
Deutsche Forschungsgemeinschaft | SFB1074 |